Evaluation of Echinacea for the Common Cold

This study has been completed.

Sponsor:

Information provided by:

National Center for Complementary and Integrative Health (NCCIH)

ClinicalTrials.gov Identifier:

NCT00032500

First received: March 22, 2002

Last updated: August 17, 2006

Last verified: July 2006

History of Changes

Purpose

The purpose of this study is to determine whether three Echinacea preparations with different chemical compositions are effective for prevention or treatment of the common cold.

Condition	Intervention	Phase
Common Cold	Drug: Echinacea	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Prevention
Official Title:	Evaluation of Echinacea in a Human Rhinovirus Challenge

Resource links provided by NLM:

MedlinePlus related topics: Common Cold

Drug Information available for: Echinacea

U.S. FDA Resources

Further study details as provided by National Center for Complementary and Integrative Health (NCCIH):


Study Start Date:	September 2001
Estimated Study Completion Date:	May 2004

Detailed Description:

Echinacea is a widely used herbal remedy for the common cold. Previous clinical trials designed to assess the efficacy of Echinacea for prevention or treatment of the common cold have produced inconsistent results. A variety of different Echinacea products have been used in these clinical trials. Recent studies indicate that different Echinacea preparations have dramatically different phytochemical profiles. The available clinical trial data provide no information about the potential role of the different constituents of Echinacea in common cold prevention or treatment. Our hypothesis is that the variation in reported clinical effectiveness may be due to differences in the phytochemical profile of the Echinacea preparations used. This study will address the following specific aims: 1) Evaluate the effectiveness of chemically defined extracts of E. angustifolia root which contain alkamides, echinacoside or polysaccharidelglycoprotein for common cold prevention or treatment; 2) Assess the correlation between specific Echinacea metabolites in serum and nasal secretions and efficacy for prevention and treatment of colds; and 3) Determine the effect of different Echinacea preparations on the host response to rhinovirus infection.

Eligibility


Ages Eligible for Study:	Child, Adult, Senior

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00032500

Locations


United States, Virginia
University of Virginia, Charlottesville
Charlottesville, Virginia, United States, 22904

Sponsors and Collaborators

National Center for Complementary and Integrative Health (NCCIH)

Investigators


Principal Investigator:	Ronald B. Turner, MD	University of Virginia School of Medicine
OverallOfficial:	J. David Gangemi, PhD	Clemson University
OverallOfficial:	Rudolf Bauer, PhD	Karl-Franzens-Universitaet Graz

More Information

Publications:

Turner RB, Bauer R, Woelkart K, Hulsey TC, Gangemi JD. An evaluation of Echinacea angustifolia in experimental rhinovirus infections. N Engl J Med. 2005 Jul 28;353(4):341-8.


ClinicalTrials.gov Identifier:	NCT00032500 History of Changes
Other Study ID Numbers:	R01AT001146-01 ( U.S. NIH Grant/Contract )
Study First Received:	March 22, 2002
Last Updated:	August 17, 2006

Keywords provided by National Center for Complementary and Integrative Health (NCCIH):


common cold Echinacea

Additional relevant MeSH terms:


Common Cold Picornaviridae Infections RNA Virus Infections	Virus Diseases Respiratory Tract Infections Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 17, 2017

To Top